Scarica l'app Stockscreener
57.98
0.03%
0.02
Precedente Chiudi:
$57.96
Aprire:
$57.94
Volume 24 ore:
899.53K
Relative Volume:
0.40
Capitalizzazione di mercato:
$1.68B
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-19.01
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
+0.10%
1M Prestazione:
+0.64%
6M Prestazione:
+397.68%
1 anno Prestazione:
+564.91%
Intervallo 1D:
$57.94
$57.99
Intervallo di 1 settimana:
$57.89
$57.99
Portata 52W:
$5.6652
$57.99
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
57.98 | 1.68B | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Piper Sandler | Overweight |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-26 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Downgrade | Stifel | Buy → Hold |
| 2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-22 | Downgrade | UBS | Buy → Neutral |
| 2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Iniziato | Evercore ISI | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-09-14 | Iniziato | Berenberg | Buy |
| 2023-08-09 | Iniziato | Stifel | Buy |
| 2023-06-15 | Iniziato | Barclays | Overweight |
| 2023-01-04 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | CapitalOne | Overweight |
| 2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Iniziato | JP Morgan | Overweight |
| 2021-08-12 | Iniziato | SVB Leerink | Outperform |
| 2021-06-21 | Iniziato | Piper Sandler | Overweight |
| 2020-06-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Iniziato | ROTH Capital | Buy |
| 2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-25 | Iniziato | UBS | Buy |
| 2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power PlayGSK (NYSE:GSK) - Benzinga
GSK acquisition of Rapt Therapeutics receives regulatory clearance in the US - MLex
RTW INVESTMENTS, LP Acquires Additional Shares in RAPT Therapeutics Inc - GuruFocus
Rapt Therapeutics stock hits 52-week high at 57.87 USD By Investing.com - Investing.com South Africa
Rapt Therapeutics stock hits 52-week high at 57.87 USD - Investing.com Australia
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Biggest stock movers Tuesday: NVDA, RAPT, MMM and more - MSN
RAPT THERAPEUTICS INC (NASDAQ:RAPT) Shows High Technical and Pattern Scores Ahead of Potential Breakout - ChartMill
Rapt Therapeutics (NASDAQ:RAPT) Sets New 52-Week HighHere's Why - MarketBeat
Is RAPT Therapeutics Inc a speculative investmentStop Loss & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Small Cap Stocks To Watch NowFebruary 13th - MarketBeat
Best Pharmaceutical Stocks To Follow TodayFebruary 13th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Growth in Short Interest - MarketBeat
Is RAPT Therapeutics Inc. stock vulnerable to regulatory risksEarnings Performance Report & Verified Swing Trading Watchlist - mfd.ru
Can RAPT Therapeutics Inc. withstand a market correctionCPI Data & AI Based Buy and Sell Signals - mfd.ru
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations - Intellectia AI
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? - Morningstar
Top Pharmaceutical Stocks To ConsiderFebruary 10th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Why did RAPT stock surge 63% in pre-market today? - MSN
Pharma deal value falls in January 2026 amid lower M&A activity: GlobalData - Express Pharma
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders - marketscreener.com
RAPT Therapeutics Proposed Sale to GSK Under Investigation - Intellectia AI
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc.RAPT - ChartMill
Rapt Therapeutics (NASDAQ:RAPT) Hits New 12-Month HighHere's Why - MarketBeat
GSK's Acquisition Highlights Trend Towards Convenience-Focused D - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-JHG, FOLD, RAPT, and EXAS - The Malaysian Reserve
GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapy - MSN
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—JHG, FOLD, RAPT, and EXAS - Morningstar
Rapt Therapeutics stock reaches 52-week high at $57.71 By Investing.com - Investing.com Nigeria
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 12-Month HighStill a Buy? - MarketBeat
Rapt Therapeutics stock reaches 52-week high at $57.71 - Investing.com
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Sahm
RAPT Therapeutics jumps 64% after GSK tables $2.2bn takeover proposal - MSN
GSK acquires RAPT Therapeutics for $2.2bn - MSN
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Biggest stock movers Tuesday: NVDA, RAPT, and more - MSN
Rapt Therapeutics stock hits 52-week high at $57.62 By Investing.com - Investing.com Nigeria
RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion - Stocktwits
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):